Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2016

Open Access 01-12-2016 | Research article

Inhibitory actions of selected natural substances on formation of advanced glycation endproducts and advanced oxidation protein products

Authors: Ewa Grzebyk, Agnieszka Piwowar

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Login to get access

Abstract

Background

Advanced glycation endproducts (AGE) and advanced oxidation protein products (AOPP) arise as a result of excessive glycation and oxidation processes of proteins in hyperglycemia and oxidative stress conditions respectively, both in vivo and in vitro. In vivo these processes are especially intensified in patients with diabetes, and the adverse effects of AGE and AOPP are particularly unfavorable for the pathogenesis and aggravate the biochemical disturbances and clinical complications of diabetes. Total AGE and AOPP (T-AGE and T-AOPP) are heterogeneous groups of compounds, and they can be divided into two main fractions: high- and low-molecular-weight, i.e. HMW-AGE and HMW-AOPP as well as LMW-AGE and LMW-AOPP. Therefore it is important to find natural substances that will prevent formation of total AGE and AOPP and their high- and low-molecular-weight fractions and thereby reduce their adverse effects on tissues and organs.

Method

Selected natural substances and dietary supplements such as vitamin C, aminoguanidine, quercetin and green tea as well as the multicompound formulations Padma Circosan and Padma 28 were tested in an in vitro model using bovine serum albumin (BSA). Fluorescence of T-, HMW- and LMW-AGE and concentration of T-, HMW- and LMW-AOPP were measured after incubation with these substances.

Results

In the examined concentrations quercetin showed the greatest degree of inhibition for T-AGE (60.5 %) as well as for HMW-AGE (79.5 %), while in the case of LMW-AGE the greatest degree of glycation inhibition was shown by Padma Circosan (74.9 %). T-AOPP and HMW-AOPP were best inhibited by vitamin C (87.3 and 89.1 % respectively). The results obtained for LMW-AOPP are atypical, but the lowest concentration was observed in a sample with Padma 28.

Conclusion

The results show that all tested natural compounds have inhibitory activity towards the formation of total and low- and high-molecular-weight forms of AGE and AOPP in vitro. That suggest a possible role in the prevention of diabetic complications, especially the multiherbal compound Padma preparations, which are especially effective in lowering the most dangerous, i.e. LMW fractions.
Literature
1.
Grzebyk E, Piwowar A. Modyfikacje glikooksydacyjne albuminy w badaniach medycznych. Pol Merk Lek. 2013;34:239–42.
2.
Kalousová M, Krha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51:597–604.PubMed
3.
Thomas M, Tsalamandris C, MacIsaac R, Medley T, Kingwell B, Cooper M, Jerums G. Low-molecular weight AGEs are associated with GFR and anemia in patients with 2 diabetes. Kidney Int. 2003;66:1167–72.CrossRef
4.
Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003;419:31–40.CrossRefPubMed
5.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kid Int. 1996;49:1304–13.CrossRef
6.
Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am. 2013;42:697–719.CrossRefPubMed
7.
Vinson JA, Howard TB. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J Nutr Biochem. 1996;7:659–63.CrossRef
8.
Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Molec Metab. 2014;3:94–108.CrossRef
9.
Thomas M, Forbes J, MacIsaac R, Jerums G, Cooper M. Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Anm N Y Acad Sci. 2005;1043:644–54.CrossRef
10.
Witko-Sarsat V, Nguyen-Khoa, Jungers P, Drueke TB, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uremia. Nephrol Dial Transplant. 1999;14:76–8.CrossRefPubMed
11.
12.
Bohlender J, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005;289:645–59.CrossRef
13.
Henle T, Deppisch R, Beck W, Hergesell O, Mänsch G, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant result with different methodologies reflecting the heterogeneity of AGEs compounds. Nephrol Dial Transplant. 1999;14:1968–75.CrossRefPubMed
14.
Piwowar A, Knapik-Kordecka M, Szczecińska J, Warwas M. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy. Diab Metab Res Rev. 2008;24:549–54.CrossRef
15.
Munesue S, Yamamoto Y, Urushihara R, Inomata K, Saito H, Motoyoshi S, Watanabe T, Yonekurad H, Yamamoto H. Low-molecular weight Fractions of Japanese soy sauce act as a RAGE antagonist via inhibition of RAGE trafficking to lipid rafts. Food Funct. 2013;4:1835–42. DOI:10.​1039/​C2FO30359.
16.
Poulsena MW, Hedegaardb RV, Andersena JM, de Courtend B, Bügela S, Nielsenc J, Skibstedb LH, Dragsted LO. Advanced glycation endproducts in food and their effects on health. Food Chem Tox. 2013;60:10–37.CrossRef
17.
Grzebyk E, Piwowar A. The Tibetan herbal medicines Padma 28 and Padma Circosan inhibit the formation of advanced glycation endproducts (AGE) and advanced oxidation protein products (AOPP) in vitro. BMC Complement Altern Med. 2014. doi:10.​1186/​1472-6882-14-287.PubMedPubMedCentral
18.
Grzebyk E, Piwowar A. Inhibition of glycoxidative modification of proteins by some substances of natural origin. Herba Pol. 2016;62(1):66–82.
19.
Ginsburg I, Rozenstein-Tsalkovich L, Koren E, Rosenmann H. The herbal preparation Padma 28 protects against neurotoxicity in PC12 cells. Phytother Res. 2011;25:740–3.CrossRefPubMed
20.
Münch G, Keis R, Weßels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 1997;35:669–77.PubMed
21.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.CrossRefPubMed
22.
Forbes JM, Soldatos G, Thomas MC. Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev. 2005;26(4):123–34.PubMedPubMedCentral
23.
Chuyen NV. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol Nutr Food Res. 2005;50:1140–9.
24.
Silva RR, Silva DO, Fontes HR. Alviano CS. Alviano DS. Anti-inflammatory, antioxidant, and antimicrobial activities of Cocos nucifera var. typica. BMC Complement Altern Med: Fernandes PD; 2013. doi:10.​1186/​1472-6882-13-107.
25.
Kerio LC, Wachira FN, Wanyoko JK, Rotich MK. Total polyphenols, catechin profiles and antioxidant activity of tea products from purple leaf coloured tea cultivars. Food Chem. 2013;136:1405–13.CrossRefPubMed
26.
Colombo G, Clerici M, Giustarini D, Portinaro N, Badalamenti S, Rossi R, Milzani A, Dalle-Donne I. A central role for intermolecular dityrosine cross-linking of fibrinogen in high molecular weight advanced oxidation protein product (AOPP) formation. Biochim Biophys Acta. 2015;1850(1):1–12.CrossRefPubMed
27.
Rajasekar P, Anuradha CV. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta Diabetol. 2007;44:83–90.CrossRefPubMed
28.
Losso JN, Bawadi HA, Chintalapati M. Inhibition of the formation of advanced glycation end products by thymoquinone. Food Chem. 2011;128:55–61.CrossRefPubMed
29.
Hou FF, Boyce J, Chertow GM, Kay J, Owen Jr WF. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Neph. 1998;9(2):277–83.
30.
Gutierrez RMP. Inhibition of advanced glycation end-product formation by origanum majorana L. in vitro and in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med. 2012;2012:598638.
31.
Stadler K, Jenei V, Jakus J. Benefical effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab Res Rev. 2005;21:189–96.CrossRefPubMed
32.
Ara C, Karabulut AB, Yilmaz M, Kirimliglu V, Yilmaz S. Protective effect of aminoguanidine against oxidative stress in an experimental peritoneal adhesion model in rats. Cell Biochem Funct. 2006;24:443–8.CrossRefPubMed
33.
34.
Shah SM, Ahmad Z, Yaseen M, Shah R, Khan S, Shah SM, Khan B. Phytochemicals, in vitro antioxidant, total phenolic contents and phytotoxic activity of Cornus macrophylla Wall bark collected from the North-West of Pakistan. Pak J Pharm Sci. 2015;28(1):23–8.PubMed
35.
Zhang HM, Wang CF, Shen SM, Wang GL, Liu P, Liu ZM, Wang YY, Du SS, Liu ZL, Deng ZW. Antioxidant phenolic compounds from Pu-erh tea. Molecules. 2012;17(12):14037–45.CrossRefPubMed
36.
Tarwadi KV, Agte VV. Effect of micronutrients on methylglyoxal-mediated in vitro glycation of albumin. Biol Trace Elem Res. 2011;143:717–25.CrossRefPubMed
37.
Lavelli V, Corey M, Kerr W, Vantaggi C. Stability and anti-glycation properties of intermediate moisture apple products fortified with green tea. Food Chem. 2011;127(2):589–95.CrossRefPubMed
38.
Djouossi MG, Tamokou JD, Ngnokam D, Kuiate JR, Tapondjou LA, Harakat D, Voutquenne-Nazabadioko L. Antimicrobial and antioxidant flavonoids from the leaves of Oncoba spinosa Forssk. (Salicaceae). BMC Complement Altern Med. 2015. doi:10.​1186/​s12906-015-0660-1.PubMedPubMedCentral
39.
Wu JW, Hsieh CL, Wang HY, Chen HY. Inhibitory effects of guava (Psidium guajava L.) leaf extracts and its active compounds on the glycation process of protein. Food Chem. 2009;113:78–84.CrossRef
40.
Wu CH, Lin JA, Hsieh WC, Yen GC. Low-density-lipoprotein (LDL)-bound flavonoids increase the resistance of LDL to oxidation and glycation under pathophysiological concentrations of glucose in vitro. J Agric Food Chem. 2009;57:5058–64.CrossRefPubMed
41.
Forester SC, Lamberd JD. The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention. Mol Nutr Food Res. 2011;55(6):844–54.CrossRefPubMedPubMedCentral
42.
Benzie I, Szeto YT. Total antioxidant capacity of teas by the ferric reducing/antioxidant power assay. J Agric Food Chem. 1999;47(2):633–6.CrossRefPubMed
43.
Almajano MP, Vila I, Gines S. Neuroprotective effects of white tea against oxidative stress-induced toxicity in striatal cells. Neurotox Res. 2011;20(4):372–8.CrossRefPubMed
44.
Neyestani TR, Shariatzade N, Kalayi A, Gharavi A, Khalaji N, Dadkhah M, Zowghi T, Haidari H, Shab-bidar S. Regular daily intake of black tea improves oxidative stress biomarkers and decreases serum C-reactive protein levels in type 2 diabetic patients. Ann Nutr Metab. 2010;57(1):40–9.CrossRefPubMed
45.
Lunceford N, Gugliucci A. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea. Fitoterapia. 2005;76:419–27.CrossRefPubMed
46.
Babu PVA, Sabitha KE, Srinivasan P, Shyamaladevi CS. Green tea attenuates diabetes induced Maillard-type fluorescence and collagen cross-linking in the heart of streptozotocin diabetic rats. Pharmacol Res. 2007;55:433–40.CrossRefPubMed
47.
Vennos C, Loepfe C. Pathogenese und pleiotrope Behandlungsansätze bei diabetischen Folgeerkrankungen – Übersicht über Wirkmechanismen von Padma 28. Schweiz Z Ganzheitsmed. 2014;26:227–33.CrossRef
Metadata
Title
Inhibitory actions of selected natural substances on formation of advanced glycation endproducts and advanced oxidation protein products
Authors
Ewa Grzebyk
Agnieszka Piwowar
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-016-1353-0

Other articles of this Issue 1/2016

BMC Complementary Medicine and Therapies 1/2016 Go to the issue

Research article

Antiosteoporotic effect of Petroselinum crispum, Ocimum basilicum and Cichorium intybus L. in glucocorticoid-induced osteoporosis in rats

Research article

Extracts of six Rubiaceae species combined with rifampicin have good in vitro synergistic antimycobacterial activity and good anti-inflammatory and antioxidant activities

Research article

Cyanidin-3-rutinoside attenuates methylglyoxal-induced protein glycation and DNA damage via carbonyl trapping ability and scavenging reactive oxygen species

Research article

Antidiabetic potential of two medicinal plants used in Gabonese folk medicine

Research article

Acthaside: a new chromone derivative from Acacia ataxacantha and its biological activities

Research article

Anti-tumor effects of Abnormal Savda Munziq on the transplanted cervical cancer (U27) mouse model